Daratumumab is effective in the relapsed or refractory systemic light‐chain amyloidosis but associated with high infection burden in a frail real‐life populationZoé Van de Wyngaert, Eileen M. Boyle, Jean‐Baptiste Bossard et al.|British Journal of Haematology|2019Cited by 29
Discontinuation of antimicrobial therapy in adult neutropenic haematology patients: A prospective cohortZoé Van de Wyngaert, S. Alfandari, Nicolas Branche et al.|International Journal of Antimicrobial Agents|2019Cited by 27
Efficacy and Safety of Daratumumab in a Frail Real-Life Relapsed or Refractory Systemic Light-Chain Amyloidosis Population (AL): Report on 15 Cases from the North of FranceZoé Van de Wyngaert, Eileen M. Boyle, Jean‐Baptiste Bossard et al.|Blood|2018Cited by 6